Allarity Therapeutics (ALLR) names Jesper Høiland to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Allarity Therapeutics Announces Changes to Board of Directors
June 11, 2025 4:05 PM EDTÂ Â Â
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenopariba differentiated, dual PARP and WNT pathway inhibitoras a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technologytoday announced that Jesper Høiland has been appointed to join the Companys Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allaritys development over the past two... More
